99mTc-PSMA SPECT/CT as a predictor of response to 177Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00029615

Enrollment

Registered

2023-09-05

Start date

2023-09-04

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Single-arm prospective observational study: patients with metastatic castration-resistant prostate cancer from September 2023 to October 2025 who received pretherapeutic imaging with 99mTc-PS

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Confirmed mCRPC, progressive disease, good general condition, exhausted recommended therapeutic options, recommendation of an interdisciplinary tumor conference.

Exclusion criteria

Exclusion criteria: Contradiction to the inclusion criteria.

Design outcomes

Primary

Measure	Time frame
PSA level and tumor volume at 12 weeks (after 2 cycles of therapy).	—

Secondary

Measure	Time frame
177Lu-PSMA uptake in posttherapeutic 177Lu-PSMA SPECT/CT.	—

Countries

Germany

Contacts

Public ContactSergey Danilov

Vivantes - Netzwerk für Gesundheit GmbH, Institut für Nuklearmedizin

sergey.danilov@vivantes.de+4930130142085

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026